Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access GSM
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
The biosimilar of Enoxaparin, a great opportunity for ROVI
The biosimilar of Enoxaparin, a great opportunity for ROVI
Find out more …
General Information
of the Company
Financial and
Economic Information
Corporate Governance
Information for Investors
Contact
Read time: 0 mins
The biosimilar of Enoxaparin, a great opportunity for ROVI
https://rovi.es/sites/default/files/The%20biosimilar%20of%20Enoxaparin%2C%20a%20great%20opportunity%20for%20ROVI%2813-03-2017%29.pdf
Year:
2017
